Treatment of uveitis with recombinant human interleukin-13
Treatment of uveitis with recombinant human interleukin-13
复制标题
重组人白细胞介素13治疗葡萄膜炎
DOI：
10.1136/bjo.82.10.1195
复制
发表时间：
1998
影响因子：
4.1
通讯作者：
J. Hakimi
中科院分区：
文献类型：
--
作者：
F. Roberge;M. D. de Smet;J. Benichou;M. Kriete;J. Raber;J. Hakimi
目的评价抗炎细胞因子白介素13(IL-13)对葡萄膜炎的治疗作用。方法用人视网膜S抗原免疫猕猴建立葡萄膜炎模型。从发病开始，动物接受IL-13治疗，剂量为25μg/kg，或赋形剂对照组，每天皮下注射一次，持续28天。采用间接检眼镜对眼内炎症反应进行评分，观察56d。监测循环中的白细胞水平。结果除1只动物外，其余动物均为单侧葡萄膜炎。IL-13抑制炎症，在治疗开始时出现疾病的眼睛(p=0.0001)，以及最初阴性的对侧眼睛(p=0.0001)。停止治疗后，IL-13治疗组炎症进行性加重。而IL-13的有益作用延续至4周随访期。IL-13使循环中的中性粒细胞增多，淋巴细胞减少。结论IL-13是治疗重症葡萄膜炎的一种有前景的方法。
AIM To evaluate the anti-inflammatory cytokine interleukin-13 (IL-13) for the treatment of uveitis. METHODS Uveitis was induced in monkeys by immunisation with human retinal S-antigen. Starting at the onset of disease, the animals were treated with IL-13 at 25 μg/kg, or vehicle control, injected subcutaneously once a day for 28 days. Intraocular inflammation was scored by indirect ophthalmoscopy for a period of 56 days. Circulating leucocyte levels were monitored. RESULTS Uveitis started unilaterally in all but one animal. IL-13 inhibited inflammation both in the eyes in which the disease was present when the treatment was initiated (p=0.0001), and in the contralateral initially negative eyes (p=0.0001). After cessation of therapy, there was a progressive increase of inflammation in the IL-13 treated group. However, the beneficial effect of IL-13 extended into the 4 week follow up period. IL-13 produced an increase in circulating polymorphonuclear neutrophils and a decrease in lymphocytes. CONCLUSION Administration of IL-13 appears to be a promising modality of treatment for severe uveitis.
对细胞因子的洞察就在眼前。
DOI：
10.1136/bjo.79.11.970
发表时间：
1995
期刊：
The British journal of ophthalmology
影响因子：
--
作者：
Rosenbaum,JT
通讯作者：
Rosenbaum,JT
影响因子：
4.4
作者：
G. Cosentino;E. Soprana;C. Thienes;A. Siccardi;G. Viale;D. Vercelli
通讯作者：
G. Cosentino;E. Soprana;C. Thienes;A. Siccardi;G. Viale;D. Vercelli